Balanced News: : Oramed’s oral insulin pill fails; stock is down 72%

Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Oramed’s treatment to placebo to see if it improved glycemic control in patients with type 2 diabetes. Oramed’s stock is down 10.7% for the past 12 months, while the broader S&P 500 SPX, +1.28% is down 15.7%.